Increased Frequency of KRAS Mutations in African Americans Compared with Caucasians in Sporadic Colorectal Cancer

Clinical and Translational Gastroenterology

Volumn 8, Issue 10, 2017, Pages E124-

  Staudacher, Jonas J ^a   Yazici, Cemal ^a   Bul, Vadim ^a   Zeidan, Joseph ^b   Khalid, Ahmer ^a   Xia, Yinglin ^a   Krett, Nancy ^a   Jung, Barbara ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN AMERICAN; APC GENE; ARTICLE; BRAF GENE; CANCER MORTALITY; CANCER PROGNOSIS; COLORECTAL CANCER; CONTROLLED STUDY; EUROPEAN AMERICAN; FBXW7 GENE; GENE; GENE MUTATION; HUMAN; MUTATION RATE; ONCOGENE K RAS; PI3CA GENE; RACE DIFFERENCE; SMAD4 GENE; SPORADIC DISEASE; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE;

EID: 85039788387     PISSN: 2155384X     EISSN: None     Source Type: Journal    
DOI: 10.1038/ctg.2017.48     Document Type: Article

References (37)

1. American Cancer Society. Cancer Facts & Figures 2017. American Cancer Society: Atlanta, GA, 2017.
2. Troisi RJ, Freedman AN, Devesa SS. Incidence of colorectal carcinoma in the US: an update of trends by gender, race, age, subsite, and stage, 1975–1994. Cancer 1999; 85: 1670–1676.
3. Karami S, Young HA, Henson DE. Earlier age at diagnosis: another dimension in cancer disparity? Cancer Detect Prev 200; 31: 29–34.
4. Robbins AS, Siegel RL, Jemal A. Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008. J Clin Oncol 2012; 30: 401–405.
5. Satia JA, Tseng M, Galanko JA et al. Dietary patterns and colon cancer risk in Whites and African Americans in the North Carolina Colon Cancer Study. Nutr Cancer 2009; 61: 179–193.
6. Yazici C, Wolf PG, Kim H et al. Race-dependent association of sulfidogenic bacteria with colorectal cancer. Gut 2017.
7. Ashktorab H, Paydar M, Yazdi S et al. BMI and the risk of colorectal adenoma in African-Americans. Obesity (Silver Spring, MD) 2014; 22: 1387–1391.
8. Aarts MJ, Lemmens VE, Louwman MW et al. Socioeconomic status and changing inequalities in colorectal cancer? A review of the associations with risk, treatment and outcome. Eur J Cancer 2010; 46: 2681–2695.
9. Ward E, Jemal A, Cokkinides V et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 2004; 54: 78–93.
10. Dachs GU, Currie MJ, McKenzie F et al. Cancer disparities in indigenous Polynesian populations: Maori, Native Hawaiians, and Pacific people. Lancet Oncol 2008; 9: 473–484.
11. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014; 64: 104–117.
12. Holme O, Bretthauer M, Fretheim A et al. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev 2013; 9: CD009259.
13. Hoffman-Goetz L, Breen NL, Meissner H. The impact of social class on the use of cancer screening within three racial/ethnic groups in the United States. Ethn Dis 1998; 8: 43–51.
14. Cho KR, Vogelstein B. Genetic alterations in the adenoma–carcinoma sequence. Cancer 1992; 70: 1727–1731.
15. Kang M, Shen XJ, Kim S et al. Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer. Cancer Biomark 2013; 13: 359–366.
16. Xicola RM, Gagnon M, Clark JR et al. Excess of proximal microsatellite-stable colorectal cancer in African Americans from a multiethnic study. Clin Cancer Res 2014; 20: 4962–4970.
17. Guda K, Veigl ML, Varadan V et al. Novel recurrently mutated genes in African American colon cancers. Proc Natl Acad Sci USA 2015; 112: 1149–1154.
18. Yoon HH, Shi Q, Alberts SR et al. Racial differences in BRAF/KRAS mutation rates and survival in stage III colon cancer patients. J Natl Cancer Inst 2015; 107: 1–10.
19. Ashktorab H, Ahuja S, Kannan L et al. A meta-analysis of MSI frequency and race in colorectal cancer. Oncotarget 2016; 7: 34546–34557.
20. Tamborero D, Gonzalez-Perez A, Perez-Llamas C et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep 2013; 3: 2650.
21. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330–337.
22. Perea JF. The Black/White binary paradigm of race: the "normal science" of American racial thought. Calif Law Rev 1997; 85: 1213–1258.
23. Lurje G, Nagashima F, Zhang W et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res 2008; 14: 7884–7895.
24. Wells GA, Shea B, O'Connell D et al. The Newcastle–Ottawa scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
25. Hanna MC, Go C, Roden C et al. Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PLoS ONE 2013; 8: e74950.
26. Katkoori VR, Jia X, Shanmugam C et al. Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res 2009; 15: 2406–2416.
27. Alberts SR, Sargent DJ, Nair S et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012; 307: 1383–1393.
28. Cohn AL, Shumaker GC, Khandelwal P et al. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2011; 10: 171–177.
29. Freeman DJ, Juan T, Reiner M et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 2008; 7: 184–190.
30. Garrido-Laguna I, Hong DS, Janku F et al. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS ONE 2012; 7: e38033.
31. Morris VK, Lucas FA, Overman MJ et al. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol 2014; 25: 2008–2014.
32. Sylvester BE, Huo D, Khramtsov A et al. Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res 2012; 18: 350–359.
33. Brim H, Mokarram P, Naghibalhossaini F et al. Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer 2008; 7: 68.
34. Thaler J, Karthaus M, Mineur L et al. Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BMC Cancer 2012; 12: 438.
35. Ganesan P, Janku F, Naing A et al. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther 2013; 12: 2857–2863.
36. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374–379.
37. Bryc K, Durand EY, Macpherson JM et al. The genetic ancestry of African Americans, Latinos, and European Americans across the United States. Am J Hum Genet 2015; 96: 37–53.